Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...

The Boston-based biotech will use the new fundraise to develop its pipeline of drug candidates for conditions such as major ...

The acquisition will add a late-stage drug candidate with blockbuster potential to Lundbeck’s neuroscience pipeline.

Investors and big pharma companies are waking up to the potential of techbio companies after years of avoidance, say experts ...